Optimizing Outcomes for Patients With CKD and T2DM
Steps that need to be taken to address unmet needs and optimize outcomes for patients who have chronic kidney disease and type 2 diabetes.
Emerging Therapies for Chronic Kidney Disease
An overview of therapies in the pipeline, including other nonsteroidal MRAs, that show potential in treating patients who have chronic kidney disease and type 2 diabetes.
SGLT2 Inhibitor Use in Chronic Kidney Disease
A panel of clinicians react to limitations surrounding the use of SGLT2 inhibitors for patients with chronic kidney disease and type 2 diabetes.
Implications of FIDELIO-DKD in CKD
Where data demonstrated by the FIDELIO-DKD study of finerenone for patients with chronic kidney disease may apply in routine clinical practice.
Non-steroidal MRAs for Chronic Kidney Disease
What to know in terms of the mechanism of action of non-steroidal MRA finerenone compared with other therapies used to treat patients with chronic kidney disease and type 2 diabetes.
The FIDELIO-DKD Trial in Chronic Kidney Disease
George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease.
Chronic Kidney Disease: Treatment Landscape
Therapies used to help treat patients who have chronic kidney disease and type 2 diabetes.
Establishing Care Pathways to Manage CKD and T2DM
Considerations for establishing balance for the care of patients with chronic kidney disease among all types of care settings.
Early Identification and Management of CKD
What better testing strategies and newer quality measures can do to improve patient referrals to nephrologists for earlier intervention of chronic kidney disease.
Measures to Improve Chronic Kidney Disease
Key takeaways from the National Kidney Foundation’s new HEDIS and MIPS quality measures for patients with chronic kidney disease and type 2 diabetes.
Care Coordination for Patients With CKD and T2DM
Various types of health care professionals who may play a role in treating patients with chronic kidney disease, and recommendations to help overcome barriers that impact risk of disease progression and outcomes for patients.
The Promising Future of Alzheimer Disease Treatment
Panelists conclude the discussion with personal insight into the promising future of Alzheimer disease treatment.
Disease-Modifying Therapy: Defining Response
Expert panelists consider how to define response to disease-modifying therapies and discuss the threshold for treatment ineligibility due to lack of response.
Motivating Patients Who Have CKD and T2DM
Strategies that can help clinicians establish and work toward goals when treating patients with chronic kidney disease to help control disease and prevent progression.
Preventing Progression of Chronic Kidney Disease
A panel of clinicians explain why action is needed to help prevent the risk of progression of chronic kidney disease.
The American Brain Foundation: Driving AD Treatment Development
A member of the American Brain Foundation discusses the organization’s role in the development of Alzheimer disease management and improvement in education.
Offsetting the Increased Cost of AD Treatment
Key opinion leaders discuss possible ways to mitigate the increased cost of Alzheimer disease treatment.
Clinical and Economic Burden of Chronic Kidney Disease
Financial and clinical concerns surrounding the burden of chronic kidney disease progression, as well as social determinants that factor into managing the condition in the community.
Counseling Patients About Chronic Kidney Disease
Strategies to help clinicians talk with patients about chronic kidney disease staging and what to expect in terms of prognosis.
Stratifying Patients for Treatment Eligibility
A discussion on the stratification of patient populations for treatment eligibility based on various decision factors.
Developing Policies for Early Biomarker Detection
Panelists discuss how to craft future policies for early biomarker detection to use developing therapies that target underlying pathophysiology.
Assessment and Staging of Chronic Kidney Disease
Diagnostic criteria and special considerations of nephrologists when assessing patient kidney function and diagnosing chronic kidney disease.
Characteristics of Chronic Kidney Disease
Drs Rajiv Agarwal and Eugene Wright Jr. highlight risk factors associated with chronic kidney disease and react to concerns surrounding the assessment and treatment of patients.
Improving Access to Appropriate AD Care
Key opinion leaders consider effective ways to improve access to appropriate care for individuals with Alzheimer disease.
Improved Tracking of AD Comorbidities and Progression
Expert panelists discuss methods to better monitor comorbidities and adverse effects associated with Alzheimer disease.
Goals of AD Therapy With Early Detection
Experts in the management of Alzheimer disease consider the future goals of therapy in tandem with the development of early detection polices.
Diagnostic Process for Individuals With Suspected AD
A discussion on the typical journey of a patient with Alzheimer disease from initial presentation to proper diagnosis within the health care system.
Key Drivers for Health Care Utilization and Spending
Key opinion leaders discuss which factors contribute to patients and caregivers deciding to seek health care guidance and assistance for Alzheimer disease.
Health Inequities Among Patient Populations With AD
A discussion on the disparity in access to quality health care between various patient populations.
Increased Prevalence of Alzheimer Disease
Experts in the management of Alzheimer disease consider the increased prevalence of Alzheimer disease in the United States with growing geriatric populations and how the health care system is adapting.
